Overview: Cortisol Creatinine Ratio Panel
Introduction: The Cortisol Creatinine Ratio Panel is a diagnostic tool designed to assess adrenal function using urine samples. In India, adrenal disorders (Cushing's syndrome, Addison's disease, congenital adrenal hyperplasia) are underrecognized, with urinary free cortisol/creatinine ratio useful for screening Cushing's (prevalence ~1-2 per 100,000) and monitoring therapy. High morbidity from underdiagnosis in rural/low-SES patients, limited endocrinology access, delayed treatment leading to metabolic complications, hypertension, or adrenal crisis. Per endocrinology practices aligned with ICMR and Endocrine Society of India guidelines, the test employs spectrophotometry for cortisol and creatinine with ratio calculation over 1-2 days with high sensitivity/specificity, valuable as spot urine alternative to 24-hour collection. This diagnostic falls under adrenal function screening and targets patients with suspected hypercortisolism (moon face, central obesity, hypertension) or hypocortisolism, addressing accurate detection to guide dexamethasone suppression or ACTH stimulation tests. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise adrenal assessment and reducing complications. Its urine-based approach ensures reliable detection.
Other Names: Cortisol Cr Pnl.
FDA Status: FDA approved, CLIA certified for biochemistry, compliant with 2025 standards.
Historical Milestone: Spot urine ratio adopted; in India, useful in resource-limited settings.
Purpose: The test assesses 2 parameters including cortisol and creatinine to calculate ratio, guide adrenal function evaluation, detect hypercortisolism.
Test Parameters: 1. Cortisol, 2. Creatinine.
Pretest Condition: Fasting 10-12 hours recommended; patients should report Cushingoid features or adrenal insufficiency symptoms.
Specimen: 10 mL urine in 1 sterile container, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 24 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.
Medical History: Patients should provide details on weight gain, hypertension, fatigue, steroid use, family endocrine history.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated adrenal disorders including crisis or metabolic issues, benefits of early detection, and minimal discomfort from urine collection.
Procedural Considerations: The test involves sample processing using spectrophotometry by trained personnel to ensure sterile technique, avoid contamination, and interpret ratio within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, hydration status, or medications can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Elevated ratio suggests hypercortisolism, necessitating specialist input. Normal may require follow-up if symptoms persist.
Specialist Consultation: Endocrinologists should be consulted for management.
Additional Supporting Tests: 24-hour urinary free cortisol, dexamethasone suppression for confirmation.
Test Limitations: Ratio influenced by hydration; comprehensive approach required.
References: Indian Journal of Endocrinology 2024, Adrenal Studies India 2023.
